GET DAILY SIGNALSPharmaCyte Biotech (PMCB) Holds Near $0.40 as Nasdaq Deadline Approaches
Key Takeaways
- PMCB shares have traded largely flat over the past 30 days, oscillating between roughly $0.30 and $0.43 and hovering near $0.40 in early November.
- PharmaCyte Biotech is a pre-revenue, clinical-stage biotechnology company built around its Cell-in-a-Box live-cell encapsulation platform and its CypCaps candidate for pancreatic cancer and other solid tumors.
- The company's lead Investigational New Drug application for locally advanced, inoperable pancreatic cancer has remained under an FDA clinical hold, keeping the core program in a research-and-review phase.
- A November 30, 2026 Nasdaq deadline to regain the $1.00 minimum bid price is a central near-term risk, with a reverse stock split authorized as a potential remedy.
- The company reported roughly $17.7 million in cash as of July 31, 2026, providing an operating runway even as it continues to post quarterly losses.
- For more detail on analyst expectations and valuation, explore PharmaCyte Biotech's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-powered trading systems are positioning across the market.
Market Snapshot for PMCB
PharmaCyte Biotech trades as a thinly covered micro-cap stock, with a market capitalization of only a few million dollars and a 52-week range spanning roughly $0.30 to $1.51. Over the trailing month, the shares have stayed within a relatively narrow band, dipping toward the low $0.30s in late October before recovering to the low $0.40s by early November. The net 30-day move has been approximately flat to slightly lower, keeping the stock well below its 52-week highs.
Sentiment around the name remains cautious. Investors are weighing a meaningful cash balance against structural concerns, including a long-standing FDA clinical hold, disclosed material weaknesses in internal controls, and a pending Nasdaq minimum-bid-price compliance deadline. These factors have kept volatility elevated in a stock where relatively small order flows can produce outsized percentage swings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Position
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes. Its core technology, Cell-in-a-Box, is a proprietary cellulose-based live-cell encapsulation platform designed to hold genetically engineered human cells that can convert an inactive chemotherapy drug into its active, cancer-killing form near the site of a tumor. The current-generation product candidate, CypCaps, is being developed for locally advanced, inoperable pancreatic cancer and other solid tumors, with additional early-stage interest in diabetes and malignant ascites.
The company is pre-revenue, maintains a very small team, and has no approved products. Its value proposition rests on the clinical and strategic optionality of its encapsulation platform, its licensing arrangements, and a balance sheet that has been supplemented by monetizing equity stakes in other life-science companies, including a previously held position in Femasys. Because the pipeline is early-stage and the lead program remains on regulatory hold, investors follow PMCB primarily for its cash position, its path to resolving the clinical hold, and the outcome of its broader strategic review.
Recent Developments
Several governance and regulatory developments have shaped investor sentiment in the recent period. The company replaced its independent auditor, dismissing CBIZ CPAs and engaging Grassi & Co. effective October 14, 2026. The change was not driven by an accounting disagreement, but filings reiterated previously disclosed material weaknesses in internal control over financial reporting related to segregation of duties and management review controls.
At the same time, the company continues to face a November 30, 2026 deadline to regain compliance with Nasdaq's $1.00 minimum bid price requirement, with its board authorized to implement a reverse stock split if needed. Quarterly results have also reflected ongoing losses, including fair-value swings on investment holdings, while cash and cash equivalents stood near $17.7 million as of July 31, 2026. A business review committee has been evaluating strategic opportunities, including the company's relationship with the licensor of its core technology, as management works to define a path forward for the clinical program.
2026 Outlook and What Investors Should Watch
Heading into the remainder of the fiscal year, the most immediate item for investors is Nasdaq listing compliance. Whether management pursues a reverse stock split, regains the $1.00 minimum bid price through natural price action, or takes another route will likely shape the near-term narrative. A second key theme is regulatory progress: any update on the FDA clinical hold or on the company's strategic and licensing relationship tied to its Cell-in-a-Box technology would be a material catalyst for a pre-revenue pipeline company.
Capital allocation also warrants attention, as the company holds a concentrated portfolio of securities alongside its cash. Fluctuations in the fair value of those holdings have introduced notable swings in reported results. Finally, continued quarterly losses, material weaknesses in internal controls, and the need to fund any future clinical trial mean that cost discipline and access to capital remain central to the company's outlook. These factors are forward-looking considerations rather than guarantees, and outcomes will depend on regulatory, governance, and market developments. From what I see, this remains an area worth monitoring closely.
Exploring AI-Driven Trading Strategies
In my own analysis, I frequently review how algorithmic systems are approaching names like PMCB. Tickeron’s Trending AI Robots page offers a practical way to examine top-performing bots across different styles and timeframes, providing additional context on automated positioning in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PMCB's RSI Oscillator recovers from oversold territory
The RSI Oscillator for PMCB moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 25 of the 30 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 67 cases where PMCB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PMCB as a result. In 97 of 121 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for PMCB just turned positive on November 03, 2026. Looking at past instances where PMCB's MACD turned positive, the stock continued to rise in 42 of 58 cases over the following month. The odds of a continued upward trend are 72%.
PMCB moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +22.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMCB advanced for three days, in 154 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
PMCB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PMCB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.138) is normal, around the industry mean (3.498). P/E Ratio (-0.173) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. PMCB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMCB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement